GemVax&KAEL Co.,Ltd. (KOSDAQ:082270)

GemVax&KAEL Statistics

Total Valuation

GemVax&KAEL has a market cap or net worth of KRW 748.99 billion. The enterprise value is 787.11 billion.

Market Cap	748.99B
Enterprise Value	787.11B

Important Dates

The next estimated earnings date is Friday, May 22, 2026.

Earnings Date	May 22, 2026
Ex-Dividend Date	n/a

Share Statistics

GemVax&KAEL has 43.95 million shares outstanding. The number of shares has increased by 4.09% in one year.

Current Share Class	43.95M
Shares Outstanding	43.95M
Shares Change (YoY)	+4.09%
Shares Change (QoQ)	+0.76%
Owned by Insiders (%)	1.13%
Owned by Institutions (%)	4.34%
Float	32.50M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	9.19
PB Ratio	13.09
P/TBV Ratio	13.90
P/FCF Ratio	6,729.49
P/OCF Ratio	675.69
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-69.43
EV / Sales	9.65
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	7,071.95

Financial Position

The company has a current ratio of 0.66, with a Debt / Equity ratio of 1.06.

Current Ratio	0.66
Quick Ratio	0.45
Debt / Equity	1.06
Debt / EBITDA	7.52
Debt / FCF	547.11
Interest Coverage	0.57

Financial Efficiency

Return on equity (ROE) is -26.29% and return on invested capital (ROIC) is 2.14%.

Return on Equity (ROE)	-26.29%
Return on Assets (ROA)	1.53%
Return on Invested Capital (ROIC)	2.14%
Return on Capital Employed (ROCE)	4.06%
Weighted Average Cost of Capital (WACC)	9.76%
Revenue Per Employee	447.97M
Profits Per Employee	-62.29M
Employee Count	182
Asset Turnover	0.53
Inventory Turnover	6.51

Taxes

Income Tax	-90.48M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -54.56% in the last 52 weeks. The beta is 1.02, so GemVax&KAEL's price volatility has been similar to the market average.

Beta (5Y)	1.02
52-Week Price Change	-54.56%
50-Day Moving Average	28,883.80
200-Day Moving Average	38,663.70
Relative Strength Index (RSI)	21.30
Average Volume (20 Days)	299,489

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, GemVax&KAEL had revenue of KRW 81.53 billion and -11.34 billion in losses. Loss per share was -274.98.

Revenue	81.53B
Gross Profit	34.82B
Operating Income	3.79B
Pretax Income	-11.43B
Net Income	-11.34B
EBITDA	8.10B
EBIT	3.79B
Loss Per Share	-274.98

Balance Sheet

The company has 22.78 billion in cash and 60.89 billion in debt, with a net cash position of -38.12 billion or -867.15 per share.

Cash & Cash Equivalents	22.78B
Total Debt	60.89B
Net Cash	-38.12B
Net Cash Per Share	-867.15
Equity (Book Value)	57.23B
Book Value Per Share	1,350.82
Working Capital	-22.52B

Cash Flow

In the last 12 months, operating cash flow was 1.11 billion and capital expenditures -997.19 million, giving a free cash flow of 111.30 million.

Operating Cash Flow	1.11B
Capital Expenditures	-997.19M
Depreciation & Amortization	4.31B
Net Borrowing	15.73B
Free Cash Flow	111.30M
FCF Per Share	2.53

Margins

Gross margin is 42.70%, with operating and profit margins of 4.65% and -13.90%.

Gross Margin	42.70%
Operating Margin	4.65%
Pretax Margin	-14.02%
Profit Margin	-13.90%
EBITDA Margin	9.94%
EBIT Margin	4.65%
FCF Margin	0.14%

Dividends & Yields

GemVax&KAEL does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-4.09%
Shareholder Yield	-4.09%
Earnings Yield	-1.51%
FCF Yield	0.01%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

GemVax&KAEL has an Altman Z-Score of 9.86 and a Piotroski F-Score of 7.

Altman Z-Score	9.86
Piotroski F-Score	7